Molecular Predictors of Pemetrexed and Carboplatin Response in Tumor Samples of a Series of Malignant Pleural Mesothelioma (MPM) Patients and Genotyping for the TSER Polymorphism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by Istituto Clinico Humanitas.
Recruitment status was  Active, not recruiting
Information provided by:
Istituto Clinico Humanitas Identifier:
First received: March 23, 2009
Last updated: September 1, 2010
Last verified: September 2010

The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.

Malignant Pleural Mesothelioma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients

Resource links provided by NLM:

Further study details as provided by Istituto Clinico Humanitas:

Primary Outcome Measures:
  • Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate retrospectively the correlation between gene expression and polymorphisms in candidate genes and array-CGH data, immunohistochemistry data, and clinical data. [ Time Frame: one year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

The paraffin-embedded tumor specimens of patients will be collected. The tumor RNA and DNA will be extracted and genotyping, gene expression and gene copy number analyses will be performed with validated PCR and array-CGH techniques.

Estimated Enrollment: 100
Study Start Date: January 2009
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Detailed Description:

Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor prognosis. The combination of cisplatin and pemetrexed has recently become the standard of care in the first-line treatment of MPM. For patients who are unfit to receive a cisplatin-based chemotherapy, pemetrexed alone [7] or combined with carboplatin [8] has been proposed as an alternative treatment choice. The identification of molecular predictors of effective therapy is important for maximizing therapeutic efficacy and minimizing useless treatment in cancer patients.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Malignant Pleural Mesothelioma patients treated with carboplatin and pemetrexed


Inclusion Criteria:

  • Availability of tumor tissue.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00867711

Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089
Sponsors and Collaborators
Istituto Clinico Humanitas
Principal Investigator: Armando Santoro, MD Istituto Clinico Humanitas
  More Information

No publications provided by Istituto Clinico Humanitas

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Armando Santoro, MD, Istituto Clinico Humanitas Identifier: NCT00867711     History of Changes
Other Study ID Numbers: ONC/OSS-04/2008
Study First Received: March 23, 2009
Last Updated: September 1, 2010
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Neoplasms, Mesothelial
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 22, 2014